We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

SpringWorks Therapeutics Inc (SWTX) USD0.0001

Sell:$37.04 Buy:$37.08 Change: $0.98 (2.71%)
NASDAQ:0.03%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$37.04
Buy:$37.08
Change: $0.98 (2.71%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$37.04
Buy:$37.08
Change: $0.98 (2.71%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Contact details

Address:
100 Washington Blvd
STAMFORD
06902-9302
United States
Telephone:
+1 (203) 8839490
Website:
https://www.springworkstx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SWTX
ISIN:
US85205L1070
Market cap:
$2.69 billion
Shares in issue:
74.39 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Saqib Islam
    Chief Executive Officer, Director
  • Francis Perier
    Chief Financial Officer
  • Badreddin Edris
    Chief Operating Officer
  • Daniel Pichl
    Chief People Officer
  • Tai-an Lin
    Chief Scientific Officer
  • Herschel Weinstein
    General Counsel, Secretary
  • Bhavesh Ashar
    Chief Commercial Officer
  • James Cassidy
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.